These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

443 related articles for article (PubMed ID: 29222348)

  • 1. Insulin degrading enzyme contributes to the pathology in a mixed model of Type 2 diabetes and Alzheimer's disease: possible mechanisms of IDE in T2D and AD.
    Li H; Wu J; Zhu L; Sha L; Yang S; Wei J; Ji L; Tang X; Mao K; Cao L; Wei N; Xie W; Yang Z
    Biosci Rep; 2018 Feb; 38(1):. PubMed ID: 29222348
    [TBL] [Abstract][Full Text] [Related]  

  • 2. cAMP/PKA signaling pathway contributes to neuronal apoptosis via regulating IDE expression in a mixed model of type 2 diabetes and Alzheimer's disease.
    Li H; Yang S; Wu J; Ji L; Zhu L; Cao L; Huang J; Jiang Q; Wei J; Liu M; Mao K; Wei N; Xie W; Yang Z
    J Cell Biochem; 2018 Feb; 119(2):1616-1626. PubMed ID: 28771808
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Insulin-degrading enzyme regulates the levels of insulin, amyloid beta-protein, and the beta-amyloid precursor protein intracellular domain in vivo.
    Farris W; Mansourian S; Chang Y; Lindsley L; Eckman EA; Frosch MP; Eckman CB; Tanzi RE; Selkoe DJ; Guenette S
    Proc Natl Acad Sci U S A; 2003 Apr; 100(7):4162-7. PubMed ID: 12634421
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Ginsenoside Rg1 decreases Aβ(1-42) level by upregulating PPARγ and IDE expression in the hippocampus of a rat model of Alzheimer's disease.
    Quan Q; Wang J; Li X; Wang Y
    PLoS One; 2013; 8(3):e59155. PubMed ID: 23520555
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Targeting Insulin-Degrading Enzyme to Treat Type 2 Diabetes Mellitus.
    Tang WJ
    Trends Endocrinol Metab; 2016 Jan; 27(1):24-34. PubMed ID: 26651592
    [TBL] [Abstract][Full Text] [Related]  

  • 6. PPARgamma transcriptionally regulates the expression of insulin-degrading enzyme in primary neurons.
    Du J; Zhang L; Liu S; Zhang C; Huang X; Li J; Zhao N; Wang Z
    Biochem Biophys Res Commun; 2009 Jun; 383(4):485-90. PubMed ID: 19383491
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Partial loss-of-function mutations in insulin-degrading enzyme that induce diabetes also impair degradation of amyloid beta-protein.
    Farris W; Mansourian S; Leissring MA; Eckman EA; Bertram L; Eckman CB; Tanzi RE; Selkoe DJ
    Am J Pathol; 2004 Apr; 164(4):1425-34. PubMed ID: 15039230
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Age-dependent impairment of glucose tolerance in the 3xTg-AD mouse model of Alzheimer's disease.
    Vandal M; White PJ; Chevrier G; Tremblay C; St-Amour I; Planel E; Marette A; Calon F
    FASEB J; 2015 Oct; 29(10):4273-84. PubMed ID: 26108977
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Interplay between Alzheimer's disease and global glucose metabolism revealed by the metabolic profile alterations of pancreatic tissue and serum in APP/PS1 transgenic mice.
    Liu X; Wang W; Chen HL; Zhang HY; Zhang NX
    Acta Pharmacol Sin; 2019 Oct; 40(10):1259-1268. PubMed ID: 31089202
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Increased Aβ production prompts the onset of glucose intolerance and insulin resistance.
    Jiménez-Palomares M; Ramos-Rodríguez JJ; López-Acosta JF; Pacheco-Herrero M; Lechuga-Sancho AM; Perdomo G; García-Alloza M; Cózar-Castellano I
    Am J Physiol Endocrinol Metab; 2012 Jun; 302(11):E1373-80. PubMed ID: 22414803
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Insulin, insulin-degrading enzyme and amyloid-beta peptide in Alzheimer's disease: review and hypothesis.
    Qiu WQ; Folstein MF
    Neurobiol Aging; 2006 Feb; 27(2):190-8. PubMed ID: 16399206
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Unexpected partial correction of metabolic and behavioral phenotypes of Alzheimer's APP/PSEN1 mice by gene targeting of diabetes/Alzheimer's-related Sorcs1.
    Knight EM; Ruiz HH; Kim SH; Harte JC; Hsieh W; Glabe C; Klein WL; Attie AD; Buettner C; Ehrlich ME; Gandy S
    Acta Neuropathol Commun; 2016 Feb; 4():16. PubMed ID: 26916443
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Insulin-resistant brain state after intracerebroventricular streptozotocin injection exacerbates Alzheimer-like changes in Tg2576 AbetaPP-overexpressing mice.
    Plaschke K; Kopitz J; Siegelin M; Schliebs R; Salkovic-Petrisic M; Riederer P; Hoyer S
    J Alzheimers Dis; 2010; 19(2):691-704. PubMed ID: 20110613
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cerebrolysin decreases amyloid-beta production by regulating amyloid protein precursor maturation in a transgenic model of Alzheimer's disease.
    Rockenstein E; Torrance M; Mante M; Adame A; Paulino A; Rose JB; Crews L; Moessler H; Masliah E
    J Neurosci Res; 2006 May; 83(7):1252-61. PubMed ID: 16511867
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effects of ageing and experimental diabetes on insulin-degrading enzyme expression in male rat tissues.
    Kochkina EG; Plesneva SA; Vasilev DS; Zhuravin IA; Turner AJ; Nalivaeva NN
    Biogerontology; 2015 Aug; 16(4):473-84. PubMed ID: 25792373
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Rosiglitazone attenuates learning and memory deficits in Tg2576 Alzheimer mice.
    Pedersen WA; McMillan PJ; Kulstad JJ; Leverenz JB; Craft S; Haynatzki GR
    Exp Neurol; 2006 Jun; 199(2):265-73. PubMed ID: 16515786
    [TBL] [Abstract][Full Text] [Related]  

  • 17. CART modulates beta-amyloid metabolism-associated enzymes and attenuates memory deficits in APP/PS1 mice.
    Yin K; Jin J; Zhu X; Yu L; Wang S; Qian L; Han L; Xu Y
    Neurol Res; 2017 Oct; 39(10):885-894. PubMed ID: 28743230
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Glucose tolerance and insulin sensitivity are impaired in APP/PS1 transgenic mice prior to amyloid plaque pathogenesis and cognitive decline.
    Macklin L; Griffith CM; Cai Y; Rose GM; Yan XX; Patrylo PR
    Exp Gerontol; 2017 Feb; 88():9-18. PubMed ID: 28025127
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cooperative therapeutic action of retinoic acid receptor and retinoid x receptor agonists in a mouse model of Alzheimer's disease.
    Kawahara K; Suenobu M; Ohtsuka H; Kuniyasu A; Sugimoto Y; Nakagomi M; Fukasawa H; Shudo K; Nakayama H
    J Alzheimers Dis; 2014; 42(2):587-605. PubMed ID: 24916544
    [TBL] [Abstract][Full Text] [Related]  

  • 20. SGLT2 and DPP4 inhibitors improve Alzheimer's disease-like pathology and cognitive function through distinct mechanisms in a T2D-AD mouse model.
    Sim AY; Choi DH; Kim JY; Kim ER; Goh AR; Lee YH; Lee JE
    Biomed Pharmacother; 2023 Dec; 168():115755. PubMed ID: 37871560
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 23.